To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Cellartis and WARF Sign License Agreement for Human Embryonic Stem Cells
Read time: Less than a minute
Cellartis AB
and the
Wisconsin Alumni Research Foundation
(WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin-Madison, announced that they have signed a license for hES patents which enables Cellartis to commercialize undifferentiated hES cell products in the US.
"This is another significant and timely step forward for Cellartis and we are delighted to make this announcement," said Mats Lundwall, CEO.
"Our business is at an exciting point in its evolution as we broaden our range of products and drive growth through innovative collaborations. This license opens the door to the large and important US market, alongside additional emerging partnering opportunities in the US which fits well into our growth strategy,” Lundwall added.
"We are extremely pleased to announce our licensing agreement and welcome Cellartis as a new commercial partner," says Andy DeTienne, WARF's licensing manager for stem cell technologies.
"As a key provider of human embryonic stem cells and related products, we are pleased Cellartis is interested in entering the U.S. market. The expansion of Cellartis’ business strategy complements WARF’s goals for supporting growth in the human stem cell industry." He notes this licensing agreement with Cellartis reflects that commercial interest in human embryonic stem cells continues to be strong.
"This is another significant and timely step forward for Cellartis and we are delighted to make this announcement," said Mats Lundwall, CEO.
"Our business is at an exciting point in its evolution as we broaden our range of products and drive growth through innovative collaborations. This license opens the door to the large and important US market, alongside additional emerging partnering opportunities in the US which fits well into our growth strategy,” Lundwall added.
"We are extremely pleased to announce our licensing agreement and welcome Cellartis as a new commercial partner," says Andy DeTienne, WARF's licensing manager for stem cell technologies.
"As a key provider of human embryonic stem cells and related products, we are pleased Cellartis is interested in entering the U.S. market. The expansion of Cellartis’ business strategy complements WARF’s goals for supporting growth in the human stem cell industry." He notes this licensing agreement with Cellartis reflects that commercial interest in human embryonic stem cells continues to be strong.
